|Other Names||Interferon regulatory factor 6, IRF-6, IRF6|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1406a was selected from the N-term region of human IRF6. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Probable DNA-binding transcriptional activator. Key determinant of the keratinocyte proliferation-differentiation switch involved in appropriate epidermal development (By similarity). Plays a role in regulating mammary epithelial cell proliferation (By similarity). May regulate WDR65 transcription (By similarity).|
|Cellular Location||Nucleus. Cytoplasm Note=Translocates to nucleus in response to an activating signal|
|Tissue Location||Expressed in normal mammary epithelial cells. Expression is reduced or absent in breast carcinomas|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IRF6 is a member of the interferon regulatory transcription factor (IRF) family. Family members share a highly-conserved N-terminal helix-turn-helix DNA-binding domain and a less conserved C-terminal protein-binding domain. Mutations in this gene can cause van der Woude syndrome and popliteal pterygium syndrome. This protein is involved in palate formation.
Jakobsen,L.P., Am. J. Med. Genet. A 143 (22), 2716-2721 (2007)Vieira,A.R., Am. J. Med. Genet. A 143 (17), 2075-2078 (2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.